SCHEMBL9107524

SCHEMBL9107524

C=CCc1ccc(C(=O)OC)cc1C(=O)OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 14/20 0.49
ALDH1A1 P00352 11/20 0.49
HSD17B10 Q99714 5/20 0.49
MAPT P10636 5/20 0.49
HPGD P15428 5/20 0.49
ATM Q13315 2/20 0.49
GLA P06280 2/20 0.49
GAA P10253 2/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA7 P43166 2/20 0.45
CA9 Q16790 2/20 0.45
CA14 Q9ULX7 2/20 0.45
XDH P47989 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907323 0.91 KDM4E (0.43) KDM4EALDH1A1HSD17B10MAPTHPGD
SCHEMBL5586280 0.88 KDM4E (0.53) KDM4EALDH1A1HSD17B10MAPTHPGD
SCHEMBL28938960 0.84 CA12 (0.56) KDM4EALDH1A1HSD17B10MAPTHPGD
SCHEMBL6478663 0.84 XDH (0.57) KDM4EALDH1A1HSD17B10MAPTHPGD
SCHEMBL2770358 0.83 KDM4E (0.55) KDM4EALDH1A1HSD17B10MAPTGLA
SCHEMBL7867138 0.83 NR4A2 (0.44) KDM4EALDH1A1HSD17B10MAPTHPGD
SCHEMBL14466455 0.83 ABL1 (0.50) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL13714155 0.83 SLC6A4 (0.41) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL20455949 0.83 MAPT (0.53) KDM4EALDH1A1MAPTATMCA12
SCHEMBL542210 0.81 CA1 (0.57) KDM4EALDH1A1HSD17B10MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-B1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC (JP) 2014-03-12 EP disclosed
EP-2463276-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2012-06-13 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E KDM4E 1474/4885ALDH1A1 1799/4885HSD17B10 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.